H.C. Wainwright initiated coverage on Biohaven with a new price target
$BHVN
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of Biohaven with a rating of Buy and set a new price target of $50.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/16/2024 | $57.00 | Buy | Jefferies |
| 9/4/2024 | $55.00 | Outperform | Bernstein |
| 7/24/2024 | $58.00 | Overweight | Morgan Stanley |
| 2/16/2024 | $62.00 | Outperform | RBC Capital Mkts |
| 2/6/2024 | $59.00 | Buy | UBS |
| 12/22/2023 | $50.00 | Buy | H.C. Wainwright |
| 12/8/2023 | $58.00 | Outperform | Robert W. Baird |
| 1/24/2023 | $24.00 | Outperform | SVB Securities |
Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 millionAchieved positive topline trial results from pivotal trial with troriluzole in spinocerebellar ataxia (SCA)Troriluzole 200 mg QD dosed orally in patients with SCA met the study's primary endpoint on the change from baseline on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypesStatistically significant superiority achieved on 9 consecutive, prespecified primary and secondary endpointsBoth the study protocol and statistical analysis plan were submitted to, and reviewed by, the U.S. Food and Drug Admini
NEW HAVEN, Conn., Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closing of its underwritten public offering of 6,052,631 of its common shares, which includes the full exercise of the underwriters' option to purchase 789,473 additional common shares, at a public offering price of $47.50 per share. The gross proceeds from the offering were approximately $287.5 million before deducting underwriting discounts and commissions and offering expenses payable by Biohaven. Biohaven inte
NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing of its underwritten public offering of 5,263,158 of its common shares at a price to the public of $47.50 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $250 million before deduct
SC 13G/A - Biohaven Ltd. (0001935979) (Subject)
SC 13G/A - Biohaven Ltd. (0001935979) (Subject)
SC 13G/A - Biohaven Ltd. (0001935979) (Subject)
Jefferies initiated coverage of Biohaven with a rating of Buy and set a new price target of $57.00
Bernstein initiated coverage of Biohaven with a rating of Outperform and set a new price target of $55.00
Morgan Stanley initiated coverage of Biohaven with a rating of Overweight and set a new price target of $58.00
Morgan Stanley analyst Terence Flynn initiates coverage on Biohaven (NYSE:BHVN) with a Overweight rating and announces Price Target of $58.
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Biohaven The Trade: Biohaven Ltd. (NYSE:BHVN) Director John W Childs acquired a total of 28,400 shares at an average price of
RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.
Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)
Conference call and webcast to be held Monday, September 23, at 8:30am ET NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e
Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was
8-K - Biohaven Ltd. (0001935979) (Filer)
10-Q - Biohaven Ltd. (0001935979) (Filer)
8-K - Biohaven Ltd. (0001935979) (Filer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi
NEW HAVEN, Conn., April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy. Dr. Kozauer comes to Biohaven after an accomplished career at the U.S. Food and Drug Administration (FDA) where he served in positions of increasing responsibility, most recently as Director of the Division of Neurology 2 in the Office of New Drugs. During his tenure at the FDA, Dr. K